(Q40649152)

22 September 2017

1 reference

title

Hepatoprotection by hydrophilic bile salts (English)

1 reference

22 September 2017

Queneau PE

1

1 reference

22 September 2017

Montet JC

series ordinal

2

1 reference

22 September 2017

publication date

1 August 1994

1 reference

22 September 2017

published in

Journal of Hepatology

1 reference

22 September 2017

volume

21

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

260-268

1 reference

Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of bile salt supplementation on biliary secretion in estrogen-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Estradiol-17 beta-D-glucuronide (E-17G) cholestasis in perfused rat liver: fate of E-17G and choleretic responses to bile salts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Diminution of an acute cyclosporin-induced cholestasis by tauroursodeoxycholate in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ethinylestradiol administration selectively alters liver sinusoidal membrane lipid fluidity and protein composition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Hepatocellular uptake of cyclosporin A by simple diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Cyclosporin A and a diaziridine derivative inhibit the hepatocellular uptake of cholate, phalloidin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ethinyl estradiol on substrate uptake and efflux by isolated rat hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Inhibition of Taurocholate and Ouabain Transport in Isolated Rat Hepatocytes by Cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid therapy in the treatment of biliary atresia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Increased expression of major histocompatibility antigens in the liver as a result of cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Immunomodulatory effects of ursodeoxycholic acid on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Thermodynamic and molecular basis for dissimilar cholesterol-solubilizing capacities by micellar solutions of bile salts: cases of sodium chenodeoxycholate and sodium ursodeoxycholate and their glycine and taurine conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Aqueous bile salt-lecithin-cholesterol systems: equilibrium aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

beta-Muricholic acid; potentiometric and cholesterol-dissolving properties

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effects of Detergents on Erythrocyte Membranes: Different Patterns of Solubilization of the Membrane Proteins by Dihydroxy and Trihydroxy Bile Salts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Activation of mast cells by bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Studies on the Mechanism of Bile Salt-Induced Liposomal Membrane Damage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Tauroursodeoxycholate prevents taurocholate induced cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Partitioning of bile acids into subcellular organelles and the in vivo distribution of bile acids in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of chenodeoxycholic acid on liver structure and function in man: a stereological and biochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Hepatic injury induced by bile salts: correlation between biochemical and morphological events

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Tauro beta-muricholate is as effective as tauroursodeoxycholate in preventing taurochenodeoxycholate-induced liver damage in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Metabolism of beta-muricholic acid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Taurohyocholate, taurocholate, and tauroursodeoxycholate but not tauroursocholate and taurodehydrocholate counteract effects of taurolithocholate in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of ursodeoxycholate on the bile flow in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Cyclosporine absorption following orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980406-4

7 January 2021

10.1016/S0168-8278(05)80406-4

Identifiers

DOI

1 reference

22 September 2017

1 reference